[1]Fiolaki A,Katsanos AH,Kyritsis AP, et al. High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: a systematic review and meta-analysis[J]. Neurol Sci, 2017, 376: 112-116. [2]Good RI, McGarrity A, James TE, et al. Dual antiplatelet response during PCI: verify Now P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response[J]. Thromb Res, 2015,135:1140-1146. [3]Ardeshna D, Khare S, Jagadish PS, et al. The dilemma of aspirin resistance in obese patients[J]. Ann Transl Med, 2019, 7:404. [4]Olechowski B, Ashby A, Mariathas M, et al. Is arachidonic acid stimulation really a test for the response to aspirin? time to think again?[J]. Expert Rev Cardiovasc Ther, 2017, 15: 35-46. [5]李芳菲,刘东涛,周立春.脑小血管病患者阿司匹林抵抗的发生率及其与长期预后的关系[J].中国卒中杂志,2020,15:668-672. [6]Pamucuk B. A review of aspirin resistance: definition, possible mechanisms, detection with platelet function tests 9 and its clinical outcomes[J]. J Thromb Thrombolysis, 2007, 23:213-222. [7]Dussaillant NG, Zapata MM, Fardella BP, et al. Frequency and characteristics of aspirin resistance in chilean cardio-vascular patients[J]. Rev Med Chil, 2005, 133: 409-417. [8]Ertugrul DT, Tutal E, Yildiz M, et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2010, 95: 2897-2901. [9]Akoglu H, Agbaht K, Piskinpasa S, et al. High frequ-ency of aspirin resistance in patients with nephrotic syndrome[J]. Nephrol Dial Transplant, 2012, 27: 1460-1466. [10]杨颂,秦彦文.单基因脂代谢异常的研究进展[J].基础医学与临床, 2018, 38: 557-562. [11]Liani R, Halvorsen B, Sestili S, et al. Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients[J]. Free Radic Biol Med, 2012, 52:1318-1324. [12]Cohen HW, Crandall JP, Hailpern SM, et al. Aspirin resistance associated with HbA1c and obesity in diabetic patients[J]. J Diabetes Complications, 2008, 22: 224-228. [13]刘俊伟,李红梅,邓爱民.2型糖尿病合并脑梗死患者发生氯吡格雷抵抗的危险因素研究[J].中国临床药理学杂志, 2018, 34:521-523. effec[14]Tasdemir E, Toptas T, Demir C, et al. Aspirin resistance in patients with type Ⅱ diabetes mellitus[J]. Ups J Med Sci, 2014, 119:25-31. [15]Wisniewski A. Multifactorial background for a low biolo-gical response to anti-platelet agents used in stroke prevention[J]. Medicina (Kaunas), 2021,57:59.doi:10.3390/medicina57010059. |